Holdings Channel
Play Video: The Importance of Insider Buying


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree SNSE Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Other companies seeing insider buying close in time to when the Sensei Biotherapeutics Insider Buying occurred are:

Vector Group Insider Buying
Avenue Therapeutics Insider Buying
Karyopharm Therapeutics Insider Buying
Codexis Insider Buying
Comera Life Sciences Holdings Insider Buying
HF Foods Group Insider Buying
Five Below Insider Buying
Friedman Industries Insider Buying
Rollins Insider Buying
NerdWallet Insider Buying

Sensei Biotherapeutics insider buying image
The table below summarizes the most recent Sensei Biotherapeutics insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why Sensei Biotherapeutics insider buys are important for investors to follow.
DateInsiderPriceAmount
9-11-2023
Insider Buy
John Celebi
President and CEO
$0.85
CAGR »
$425.00
500 shares
2-23-2023
Insider Buy
Investment Group LTD. Apeiron
>10% Owner
$1.61
CAGR »
$3,539.03
2,200 shares
3-2-2022
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$3.20
CAGR »
$3,849.60
1,203 shares
2-24-2022
Insider Buy
James Peyer
Director and >10% Owner
$3.65
CAGR »
$63,950.00
17,500 shares
2-18-2022
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$4.02
CAGR »
$80,187.33
19,949 shares
2-18-2022
Insider Buy
James Peyer
Director and >10% Owner
$4.02
CAGR »
$80,187.33
19,949 shares
2-16-2022
Insider Buy
James Peyer
Director and >10% Owner
$4.19
CAGR »
$52,641.75
12,551 shares
2-16-2022
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$4.19
CAGR »
$52,641.75
12,551 shares
2-8-2022
Insider Buy
James Peyer
Director and >10% Owner
$4.53
CAGR »
$135,800.00
30,000 shares
2-8-2022
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$4.53
CAGR »
$135,800.00
30,000 shares
1-28-2022
Insider Buy
James Peyer
Director and >10% Owner
$4.26
CAGR »
$63,849.00
15,000 shares
1-28-2022
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$4.26
CAGR »
$63,849.00
15,000 shares
1-26-2022
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$4.72
CAGR »
$235,824.00
50,000 shares
1-26-2022
Insider Buy
James Peyer
Director and >10% Owner
$4.72
CAGR »
$235,824.00
50,000 shares
1-24-2022
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$4.82
CAGR »
$228,528.65
47,410 shares
1-24-2022
Insider Buy
James Peyer
Director and >10% Owner
$4.82
CAGR »
$228,528.65
47,410 shares
1-20-2022
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$5.10
CAGR »
$154,312.68
30,244 shares
1-20-2022
Insider Buy
James Peyer
Director and >10% Owner
$5.10
CAGR »
$154,312.68
30,244 shares
1-18-2022
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$5.08
CAGR »
$50,800.00
10,000 shares
1-18-2022
Insider Buy
James Peyer
Director and >10% Owner
$5.08
CAGR »
$50,800.00
10,000 shares
1-14-2022
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$5.10
CAGR »
$133,391.70
26,172 shares
1-14-2022
Insider Buy
James Peyer
Director and >10% Owner
$5.10
CAGR »
$133,391.70
26,172 shares
1-12-2022
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$5.20
CAGR »
$104,211.54
20,047 shares
1-12-2022
Insider Buy
James Peyer
Director and >10% Owner
$5.20
CAGR »
$104,211.54
20,047 shares
1-10-2022
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$5.28
CAGR »
$52,800.00
10,000 shares
1-10-2022
Insider Buy
James Peyer
Director and >10% Owner
$5.28
CAGR »
$52,800.00
10,000 shares
12-30-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$4.85
CAGR »
$5,465.95
1,127 shares
12-30-2021
Insider Buy
James Peyer
Director and >10% Owner
$4.85
CAGR »
$5,465.95
1,127 shares
12-29-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$4.98
CAGR »
$343,620.00
69,000 shares
12-29-2021
Insider Buy
James Peyer
Director and >10% Owner
$4.98
CAGR »
$343,620.00
69,000 shares
12-28-2021
Insider Buy
James Peyer
Director and >10% Owner
$5.28
CAGR »
$59,600.64
11,288 shares
12-28-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$5.28
CAGR »
$59,600.64
11,288 shares
12-27-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$5.30
CAGR »
$19,673.60
3,712 shares
12-27-2021
Insider Buy
James Peyer
Director and >10% Owner
$5.30
CAGR »
$19,673.60
3,712 shares
12-23-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$5.27
CAGR »
$57,970.00
11,000 shares
12-23-2021
Insider Buy
James Peyer
Director and >10% Owner
$5.27
CAGR »
$57,970.00
11,000 shares
12-16-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$5.25
CAGR »
$57,356.25
10,925 shares
12-10-2021
Insider Buy
Thomas G. Ricks
Director
$6.24
CAGR »
$249,600.00
40,000 shares
5-5-2021
Insider Buy
James Peyer
Director and >10% Owner
$12.00
CAGR »
$4,200.00
350 shares
4-20-2021
Insider Buy
James Peyer
Director and >10% Owner
$12.77
CAGR »
$4,916.45
385 shares
4-20-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$12.77
CAGR »
$4,916.45
385 shares
4-19-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$13.38
CAGR »
$26,291.70
1,965 shares
4-19-2021
Insider Buy
James Peyer
Director and >10% Owner
$13.38
CAGR »
$26,291.70
1,965 shares
4-13-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$14.00
CAGR »
$28,000.00
2,000 shares
4-13-2021
Insider Buy
James Peyer
Director and >10% Owner
$14.00
CAGR »
$28,000.00
2,000 shares
4-7-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$14.00
CAGR »
$28,000.00
2,000 shares
4-1-2021
Insider Buy
James Peyer
Director and >10% Owner
$14.00
CAGR »
$14,000.00
1,000 shares
4-1-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$14.00
CAGR »
$14,000.00
1,000 shares
3-30-2021
Insider Buy
James Peyer
Director and >10% Owner
$12.00
CAGR »
$24,000.00
2,000 shares
3-30-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$12.00
CAGR »
$24,000.00
2,000 shares
3-24-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$14.12
CAGR »
$52,950.00
3,750 shares
3-24-2021
Insider Buy
James Peyer
Director and >10% Owner
$14.12
CAGR »
$52,950.00
3,750 shares
3-22-2021
Insider Buy
James Peyer
Director and >10% Owner
$15.02
CAGR »
$32,788.66
2,183 shares
3-22-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$15.02
CAGR »
$32,788.66
2,183 shares
3-18-2021
Insider Buy
James Peyer
Director and >10% Owner
$15.25
CAGR »
$12,459.25
817 shares
3-8-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$15.25
CAGR »
$15,249.00
1,000 shares
3-8-2021
Insider Buy
James Peyer
Director and >10% Owner
$15.25
CAGR »
$15,249.00
1,000 shares
3-4-2021
Insider Buy
James Peyer
Director and >10% Owner
$15.16
CAGR »
$75,800.00
5,000 shares
3-4-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$15.16
CAGR »
$75,800.00
5,000 shares
2-26-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$16.25
CAGR »
$81,250.00
5,000 shares
2-22-2021
Insider Buy
James Peyer
Director and >10% Owner
$18.88
CAGR »
$185,061.76
9,802 shares
2-22-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$18.88
CAGR »
$185,061.76
9,802 shares
2-18-2021
Insider Buy
James Peyer
Director and >10% Owner
$19.75
CAGR »
$14,871.75
753 shares
2-18-2021
Insider Buy
Biopharma Inc Cambrian
>10% Owner
$19.75
CAGR »
$14,871.75
753 shares

Also See: Institutional Holders of SNSE
Also See: SEC filings

SNSE Performance Since Insider Purchase
Below we present the annualized performance delivered by Sensei Biotherapeutics stock since 9-11-2023 (the date of the most recent insider purchase). The performance of the investment from the time Sensei Biotherapeutics insider buying occurred is the ultimate test of whether insiders were right about SNSE being a good buy.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 09/12/2023
End date: 04/17/2024
Start price/share: $0.78
End price/share: $1.00
Dividends collected/share: $0.00
Total return: 28.21%
Annualized Gain: 47.22%
Starting investment: $10,000.00
Ending investment: $12,821.00
Years: 0.60

Sensei Biotherapeutics Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Sensei Biotherapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding SNSE

Sensei Biotherapeutics Insider Buying | www.HoldingsChannel.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in Holdings Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent. Contact Holdings Channel; Meet Our Editorial Staff.